Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment paradigms and enabled numerous patients to achieve disease control with an acceptable safety profile. However, the high cost of biologics limits access to these medications for the majority...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Arnon D. Cohen, Jashin J. Wu, L. Puig, Sergio Chimenti, Ronald Vender, Murlidhar Rajagopalan, Ricardo Romiti, Claudia de la Cruz, Lone Skov, Claus Zachariae, Helen Young, Peter Foley, Joelle M. van der Walt, Luigi Naldi, Errol P. Prens, Andrew Blauvelt
Format: Revisão
Sprache:Englisch
Veröffentlicht: 2017
Online-Zugang:https://doi.org/10.1111/bjd.15756
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!